• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

吉妥单抗奥唑米星治疗后经颈静脉肝内门体分流术、去纤苷和大剂量皮质类固醇成功治疗极重度窦性阻塞综合征:一例报告

Successful Treatment of Very Severe Sinusoidal Obstruction Syndrome After Gemtuzumab Ozogamicin With Transjugular Intrahepatic Portosystemic Shunt, Defibrotide, and High-Dose Corticosteroids: A Case Report.

作者信息

Thielemans Naomi, De Beule Nathan, Van den Bergh Frans, Lefesvre Pierre, De Becker Ann

机构信息

Department of Clinical Hematology, Universitair Ziekenhuis Brussel, Brussels, BEL.

Department of Interventional Radiology, Universitair Ziekenhuis Brussel, Brussels, BEL.

出版信息

Cureus. 2024 Aug 24;16(8):e67682. doi: 10.7759/cureus.67682. eCollection 2024 Aug.

DOI:10.7759/cureus.67682
PMID:39185292
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11344603/
Abstract

Sinusoidal obstruction syndrome (SOS) is a rare but potentially life-threatening complication, usually described in the setting of hematopoietic stem cell transplantation (HSCT). The very severe forms have a high mortality rate (>80%) and need fast recognition and urgent treatment. In this case report, we describe a unique and successful treatment strategy. We present a 27-year-old patient with newly diagnosed CD33+ acute myeloid leukemia (AML). She was treated with induction chemotherapy (7+3 regimen) and gemtuzumab ozogamicin (GO). In the absence of other major risk factors, she developed a very severe SOS with multiple organ failure. She was successfully treated with the urgent insertion of a transjugular intrahepatic portosystemic shunt (TIPS), defibrotide, and high-dose corticosteroids. This case of successful treatment for very severe SOS supports a combination strategy involving the immediate mechanical reduction of portal hypertension through TIPS and drug-mediated inhibition of microvascular thrombosis. Furthermore, this case shows the need for an improved prevention strategy, including the identification of additional risk factors and biomarkers.

摘要

窦性阻塞综合征(SOS)是一种罕见但可能危及生命的并发症,通常在造血干细胞移植(HSCT)的背景下被描述。非常严重的形式具有高死亡率(>80%),需要快速识别和紧急治疗。在本病例报告中,我们描述了一种独特且成功的治疗策略。我们介绍了一名27岁新诊断为CD33+急性髓系白血病(AML)的患者。她接受了诱导化疗(7+3方案)和吉妥珠单抗奥唑米星(GO)治疗。在没有其他主要危险因素的情况下,她发生了伴有多器官衰竭的非常严重的SOS。通过紧急插入经颈静脉肝内门体分流术(TIPS)、去纤苷和高剂量皮质类固醇,她得到了成功治疗。这例非常严重SOS的成功治疗病例支持一种联合策略,即通过TIPS立即机械性降低门静脉高压以及药物介导抑制微血管血栓形成。此外,该病例表明需要改进预防策略,包括识别额外的危险因素和生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cab2/11344603/f2e3380e8cf7/cureus-0016-00000067682-i04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cab2/11344603/566ceb511889/cureus-0016-00000067682-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cab2/11344603/fe574192813d/cureus-0016-00000067682-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cab2/11344603/45d8ceadd5d0/cureus-0016-00000067682-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cab2/11344603/f2e3380e8cf7/cureus-0016-00000067682-i04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cab2/11344603/566ceb511889/cureus-0016-00000067682-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cab2/11344603/fe574192813d/cureus-0016-00000067682-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cab2/11344603/45d8ceadd5d0/cureus-0016-00000067682-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cab2/11344603/f2e3380e8cf7/cureus-0016-00000067682-i04.jpg

相似文献

1
Successful Treatment of Very Severe Sinusoidal Obstruction Syndrome After Gemtuzumab Ozogamicin With Transjugular Intrahepatic Portosystemic Shunt, Defibrotide, and High-Dose Corticosteroids: A Case Report.吉妥单抗奥唑米星治疗后经颈静脉肝内门体分流术、去纤苷和大剂量皮质类固醇成功治疗极重度窦性阻塞综合征:一例报告
Cureus. 2024 Aug 24;16(8):e67682. doi: 10.7759/cureus.67682. eCollection 2024 Aug.
2
Transjugular Intrahepatic Portosystemic Shunt for Very Severe Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation with Post-transplantation Cyclophosphamide.经移植后环磷酰胺预处理的非血缘单倍体造血干细胞移植后,严重肝静脉闭塞病/窦状隙阻塞综合征(VOD/SOS)患者行经颈静脉肝内门体分流术。
Biol Blood Marrow Transplant. 2020 Nov;26(11):2089-2097. doi: 10.1016/j.bbmt.2020.08.006. Epub 2020 Aug 11.
3
Sinusoidal obstruction syndrome (hepatic veno-occlusive disease).窦性阻塞综合征(肝静脉闭塞病)
J Clin Exp Hepatol. 2014 Dec;4(4):332-46. doi: 10.1016/j.jceh.2014.10.002. Epub 2014 Oct 30.
4
BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation.BCSH/BSBMT 指南:造血干细胞移植后静脉闭塞病(窦状隙阻塞综合征)的诊断和治疗。
Br J Haematol. 2013 Nov;163(4):444-57. doi: 10.1111/bjh.12558. Epub 2013 Sep 17.
5
Prior Gemtuzumab Ozogamicin Exposure in Adults with Acute Myeloid Leukemia Does Not Increase Hepatic Veno-Occlusive Disease Risk after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis.既往接受吉妥单抗奥佐米星治疗的急性髓系白血病成人患者在异基因造血细胞移植后发生肝静脉闭塞性疾病的风险并未增加:国际血液和骨髓移植研究中心分析
Biol Blood Marrow Transplant. 2020 May;26(5):884-892. doi: 10.1016/j.bbmt.2019.12.763. Epub 2019 Dec 28.
6
Molecular Advances in Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease.窦房阻塞综合征/静脉阻塞性疾病的分子进展。
Int J Mol Sci. 2023 Mar 15;24(6):5620. doi: 10.3390/ijms24065620.
7
Veno-occlusive disease risk in pediatric patients with acute myeloid leukemia treated with gemtuzumab ozogamicin before allogeneic hematopoietic cell transplantation.在异基因造血细胞移植前接受吉妥珠单抗奥佐米星治疗的急性髓系白血病患儿的静脉闭塞性疾病风险。
Pediatr Blood Cancer. 2021 Aug;68(8):e29067. doi: 10.1002/pbc.29067. Epub 2021 Apr 19.
8
Outcomes following hematopoietic stem cell transplantation in patients treated with standard chemotherapy with or without gemtuzumab ozogamicin for acute myeloid leukemia.在接受标准化疗联合或不联合吉妥珠单抗奥佐米星治疗的急性髓系白血病患者中,造血干细胞移植的结果。
Bone Marrow Transplant. 2021 Jun;56(6):1474-1477. doi: 10.1038/s41409-020-01207-4. Epub 2021 Feb 9.
9
Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia.吉妥珠单抗奥唑米星用于急性髓系白血病相关不良事件的预防、识别与管理。
J Hematol Oncol. 2020 Oct 15;13(1):137. doi: 10.1186/s13045-020-00975-2.
10
Defibrotide Prophylaxis of Sinusoidal Obstruction Syndrome in Adults Treated With Inotuzumab Ozogamicin Prior to Hematopoietic Stem Cell Transplantation.在造血干细胞移植前接受奥英妥珠单抗治疗的成人中,去纤苷预防肝窦阻塞综合征
Front Oncol. 2022 Jun 15;12:933317. doi: 10.3389/fonc.2022.933317. eCollection 2022.

引用本文的文献

1
Defibrotide for Protecting Against and Managing Endothelial Injury in Hematologic Malignancies and COVID-19.去纤苷用于预防和治疗血液系统恶性肿瘤及新冠肺炎中的内皮损伤
Biomolecules. 2025 Jul 14;15(7):1004. doi: 10.3390/biom15071004.

本文引用的文献

1
Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial.分次与单次吉妥珠单抗奥佐米星治疗与老年 AML 患者获益相关因素:英国 NCRI AML18 试验。
Blood. 2023 Nov 16;142(20):1697-1707. doi: 10.1182/blood.2023020630.
2
Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a refined classification from the European society for blood and marrow transplantation (EBMT).成年患者肝窦阻塞综合征/静脉闭塞性疾病的诊断和严重程度标准:欧洲血液与骨髓移植学会(EBMT)的细化分类
Bone Marrow Transplant. 2023 Jul;58(7):749-754. doi: 10.1038/s41409-023-01992-8. Epub 2023 Apr 24.
3
Real-world use of defibrotide for veno-occlusive disease/sinusoidal obstruction syndrome: the DEFIFrance Registry Study.
真实世界中使用去纤维肽治疗静脉闭塞病/窦状隙阻塞综合征:DEFIFrance 登记研究。
Bone Marrow Transplant. 2023 Apr;58(4):367-376. doi: 10.1038/s41409-022-01900-6. Epub 2022 Dec 23.
4
CD33 Expression and Gentuzumab Ozogamicin in Acute Myeloid Leukemia: Two Sides of the Same Coin.CD33表达与吉妥珠单抗奥唑米星在急性髓系白血病中的作用:同一枚硬币的两面
Cancers (Basel). 2021 Jun 28;13(13):3214. doi: 10.3390/cancers13133214.
5
Outcomes following hematopoietic stem cell transplantation in patients treated with standard chemotherapy with or without gemtuzumab ozogamicin for acute myeloid leukemia.在接受标准化疗联合或不联合吉妥珠单抗奥佐米星治疗的急性髓系白血病患者中,造血干细胞移植的结果。
Bone Marrow Transplant. 2021 Jun;56(6):1474-1477. doi: 10.1038/s41409-020-01207-4. Epub 2021 Feb 9.
6
Transjugular Intrahepatic Portosystemic Shunt for Very Severe Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation with Post-transplantation Cyclophosphamide.经移植后环磷酰胺预处理的非血缘单倍体造血干细胞移植后,严重肝静脉闭塞病/窦状隙阻塞综合征(VOD/SOS)患者行经颈静脉肝内门体分流术。
Biol Blood Marrow Transplant. 2020 Nov;26(11):2089-2097. doi: 10.1016/j.bbmt.2020.08.006. Epub 2020 Aug 11.
7
Prior Gemtuzumab Ozogamicin Exposure in Adults with Acute Myeloid Leukemia Does Not Increase Hepatic Veno-Occlusive Disease Risk after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis.既往接受吉妥单抗奥佐米星治疗的急性髓系白血病成人患者在异基因造血细胞移植后发生肝静脉闭塞性疾病的风险并未增加:国际血液和骨髓移植研究中心分析
Biol Blood Marrow Transplant. 2020 May;26(5):884-892. doi: 10.1016/j.bbmt.2019.12.763. Epub 2019 Dec 28.
8
Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation.骨髓清除性干细胞移植后肝静脉闭塞病/窦状隙阻塞综合征的早期临床预测因子。
Biol Blood Marrow Transplant. 2019 Jan;25(1):137-144. doi: 10.1016/j.bbmt.2018.07.039. Epub 2018 Aug 3.
9
Combination of High-Dose Methylprednisolone and Defibrotide for Veno-Occlusive Disease in Pediatric Hematopoietic Stem Cell Transplant Recipients.大剂量甲基泼尼松龙联合去纤维肽治疗儿童造血干细胞移植后肝静脉闭塞病。
Biol Blood Marrow Transplant. 2018 Jan;24(1):91-95. doi: 10.1016/j.bbmt.2017.09.007. Epub 2017 Sep 20.
10
Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: Risk Factors and Stratification, Prophylaxis, and Treatment.造血干细胞移植后肝静脉闭塞病:危险因素与分层、预防及治疗
Biol Blood Marrow Transplant. 2016 Mar;22(3):400-9. doi: 10.1016/j.bbmt.2015.09.024. Epub 2015 Oct 23.